SFERA Archivio dei prodotti della Ricerca dell'Università di Ferrara

CAVAZZINI, Francesco
 Distribuzione geografica
Salva come PNG Salva come JPEG
Continente #
NA - Nord America 14.657
AS - Asia 8.283
EU - Europa 4.294
SA - Sud America 1.122
AF - Africa 175
OC - Oceania 20
Continente sconosciuto - Info sul continente non disponibili 7
AN - Antartide 1
Totale 28.559
Salva come PNG Salva come JPEG
Nazione #
US - Stati Uniti d'America 14.326
SG - Singapore 3.019
CN - Cina 2.014
VN - Vietnam 887
IT - Italia 881
DE - Germania 864
BR - Brasile 855
HK - Hong Kong 643
UA - Ucraina 558
TR - Turchia 523
GB - Regno Unito 443
BD - Bangladesh 419
FI - Finlandia 335
FR - Francia 269
SE - Svezia 241
RU - Federazione Russa 227
JP - Giappone 200
IN - India 160
CA - Canada 144
MX - Messico 137
PL - Polonia 121
ID - Indonesia 97
AR - Argentina 92
ZA - Sudafrica 73
NL - Olanda 64
IQ - Iraq 62
EC - Ecuador 46
BE - Belgio 45
ES - Italia 45
CZ - Repubblica Ceca 43
PK - Pakistan 33
CO - Colombia 31
LT - Lituania 31
AT - Austria 29
SA - Arabia Saudita 28
VE - Venezuela 27
CL - Cile 26
UZ - Uzbekistan 26
MY - Malesia 23
MA - Marocco 21
PH - Filippine 20
AE - Emirati Arabi Uniti 16
NP - Nepal 16
TN - Tunisia 16
AU - Australia 15
KE - Kenya 15
EG - Egitto 14
IL - Israele 14
RO - Romania 13
DZ - Algeria 12
CH - Svizzera 11
ET - Etiopia 11
PE - Perù 11
UY - Uruguay 11
BO - Bolivia 10
IE - Irlanda 10
JO - Giordania 10
PY - Paraguay 10
DK - Danimarca 9
KR - Corea 9
DO - Repubblica Dominicana 8
TH - Thailandia 8
PS - Palestinian Territory 7
AL - Albania 6
BG - Bulgaria 6
HN - Honduras 6
HR - Croazia 6
OM - Oman 6
CR - Costa Rica 5
EU - Europa 5
IR - Iran 5
JM - Giamaica 5
KZ - Kazakistan 5
LV - Lettonia 5
PT - Portogallo 5
QA - Qatar 5
TT - Trinidad e Tobago 5
AZ - Azerbaigian 4
BH - Bahrain 4
HU - Ungheria 4
LB - Libano 4
RS - Serbia 4
BB - Barbados 3
BY - Bielorussia 3
GR - Grecia 3
KG - Kirghizistan 3
LY - Libia 3
NG - Nigeria 3
NZ - Nuova Zelanda 3
PA - Panama 3
PR - Porto Rico 3
SR - Suriname 3
BA - Bosnia-Erzegovina 2
CI - Costa d'Avorio 2
EE - Estonia 2
GD - Grenada 2
GT - Guatemala 2
KW - Kuwait 2
LK - Sri Lanka 2
MT - Malta 2
Totale 28.525
Salva come PNG Salva come JPEG
Città #
Singapore 1.971
Ashburn 1.823
Woodbridge 1.238
Fairfield 1.181
San Jose 907
Houston 839
Beijing 777
Chandler 649
Hong Kong 628
Jacksonville 628
Santa Clara 612
Ann Arbor 487
Seattle 459
Wilmington 429
Cambridge 380
New York 365
Dallas 288
Los Angeles 278
Ho Chi Minh City 277
Izmir 229
Hanoi 201
Nanjing 199
Munich 192
Ferrara 191
Tokyo 184
Princeton 170
Lauterbourg 144
Helsinki 129
Boardman 120
Warsaw 117
San Diego 115
Council Bluffs 105
Shanghai 102
São Paulo 102
Milan 101
Addison 90
Turku 86
Mexico City 83
Buffalo 74
Orem 73
London 69
Shenyang 68
Jakarta 66
Nanchang 64
Chicago 60
Da Nang 54
Denver 49
Montreal 48
The Dalles 47
Brooklyn 46
Bremen 45
Chennai 45
Hebei 45
Rome 45
Brussels 43
Phoenix 42
Stockholm 42
Rio de Janeiro 41
Johannesburg 39
Tianjin 39
Toronto 38
Hefei 37
Haiphong 36
San Francisco 36
Atlanta 35
Columbus 35
Frankfurt am Main 34
Moscow 34
Falls Church 33
Redwood City 32
Changsha 31
Jinan 31
Boston 30
Poplar 30
Falkenstein 29
Manchester 29
Jiaxing 28
Guangzhou 26
Baghdad 25
Brno 25
Amsterdam 24
Mountain View 23
Zhengzhou 23
Dong Ket 22
Ankara 21
Dearborn 21
Mumbai 21
Biên Hòa 20
Bologna 20
Des Moines 20
Nuremberg 20
Belo Horizonte 19
Norwalk 19
Naples 18
Tashkent 18
Florence 17
Quito 17
Salt Lake City 17
Fidenza 16
Guayaquil 16
Totale 19.046
Salva come PNG Salva come JPEG
Nome #
In CLL, comorbidities and the complex karyotype are associated with an inferior outcome independently of CLL-IPI 316
Diagnostic work-up for clinical and prognostic assessment of acute leukaemia 292
Acute Human Herpesvirus-6A infection of human mesothelial cells modulates HLA molecules 287
Involvement of the P2X7-NLRP3 axis in leukemic cell proliferation and death 280
Chromosome aberrations detected by conventional karyotyping using novel mitogens in chronic lymphocytic leukemia: Clinical and biologic correlations. 274
Extensive next-generation sequencing analysis in chronic lymphocytic leukemia at diagnosis: Clinical and biological correlations 272
An extensive molecular cytogenetic characterization in high-risk chronic lymphocytic leukemia identifies karyotype aberrations and TP53 disruption as predictors of outcome and chemorefractoriness 270
CYTOGENETIC ABERRATIONS IN THE CD38 POSITIVE FRACTION OF CD38 NEGATIVE CHRONIC LYMPHOCYTIC LEUKEMIA (CLL) PATIENTS: A MARKER OF AGGRESSIVENESS? 269
A highly sensitive and specific fluorescence in situ hybridization (FISH) approach for the detection of t(9;11)(p22-23;q23) in acute myeloid leukemia. 266
A novel recurrent translocation t(11;14)(p11;q32) in splenic marginal zone B cell lymphoma 264
An extensive molecular cytogenetic characterization in high-risk chronic lymphocytic leukemia identifies karyotype aberrations and TP53 disruption as predictors of outcome and chemorefractoriness 263
Identifying High-Risk Chronic Lymphocytic Leukemia: A Pathogenesis-Oriented Appraisal of Prognostic and Predictive Factors in Patients Treated with Chemotherapy with or without Immunotherapy 262
Chronic lymphocytic leukemia with 6q- shows distinct hematological features and intermediate prognosis 259
Clonal evolution including 14q32/IGH translocations in chronic lymphocytic leukemia: analysis of clinicobiologic correlations in 105 patients 254
In chronic lymphocytic leukaemia with complex karyotype, major structural abnormalities identify a subset of patients with inferior outcome and distinct biological characteristics 251
Soluble urokinase-type Plasminogen Activator Receptor (suPAR) as an independent factor predicting worse prognosis and extra bone marrow involvement in multiple myeloma patients 249
Clinical importance of interphase cytogenetics detecting occult chromosome lesions in myelodysplastic syndromes with normal karyotype 246
Chromosome Aberrations by Conventional Karyotyping in Chronic Lymphocytic Leukemia Carrying No Aberration by Fluorescence in Situ Hybridization: Correlation with Prognostic Parameters and Clinical Features 244
CLINICAL AND BIOLOGICAL CHARACTERIZATION OF CIRCULATING ENDOTHELIAL CELLS IN CHRONIC LYMPHOCYTIC LEUKEMIA 243
Genetic subclonal complexity and miR125a-5p down-regulation identify a subset of patients with inferior outcome in low-risk CLL patients 241
B-Cell chronic lymphocytic leukemia (B-CLL) with 14q32 translocations: haematological features and clinical outcome. 240
Chromosome aberrations detected by conventional karyotyping using novel mitogens in chronic lymphocytic leukemia: Clinical and biologic correlations 230
Myelofibrosis with Myeloid Metaplasia (MMM)/Idiopathic myelofibrosis/Agnogenic myeloid metaplasia 230
Incidence and significance of cryptic chromosome aberrations detected by fluorescence in situ hybridization in acute myeloid leukemia with normal karyotype 228
Employment of Oligodeoxynucleotide plus Interleukin-2 Improves Cytogenetic Analysis in SplenicMarginal Zone Lymphoma 227
Age influences initial dose and compliance to imatinib in chronic myeloid leukemia elderly patients but concomitant comorbidities appear to influence overall and event-free survival 227
Age Influences Initial Dose and Compliance to Imatinib In Chronic Myeloid Leukemia Elederly Patients but Concomitant Comorbidities Appear to Influence Overall and Event-Free Survival 225
Alternating Nilotinib 400 mg twice daily and Imatinib 400 mg once daily as Frontline Treatment of Ph+ Chronic Myeloid Leukemia. A Phase 2 Multicentric Study of the GIMEMA CML Working Party 225
Adherence and future discontinuation of tyrosine kinase inhibitors in chronic phase chronic myeloid leukemia. A patient-based survey on 1133 patients 225
A Population-Based Study of Chronic Myeloid Leukemia Treated with Imatinib in First Line 225
Secondary chromosome changes in mantle cell lymphoma: Cytogenetic and fluorescence in situ hybridization studies 223
Biological significance and prognostic/predictive impact of complex karyotype in chronic lymphocytic leukemia 222
Angiogenesis in multiple myeloma: Correlation between in vitro endothelial colonies growth (CFU-En) and clinical-biological features 221
Chromosome aberrations detected by conventional karyotyping using novel mitogens in chronic lymphocytic leukemia with "normal" FISH: Correlations with clinicobiologic parameters 221
Alterazioni cromosomiche in cellule staminali emopoietiche indotte da esposizioni ambientali o professionali. 220
Erratum to: Extensive next-generation sequencing analysis in chronic lymphocytic leukemia at diagnosis: clinical and biological correlations (J Hematol Oncol. (2016) 9 (88) DOI:10.1186/s13045-016-0320-z) 220
HEMOPHAGOCYTIC LYMPHOHISTIOCYTOSIS IN A PATIENT WITH RELAPSED CHRONIC LYMPHOCYTIC LEUKEMIA TREATED WITH IBRUTINIB 220
A highly sensitive and specific fluorescence in situ hybridization (FISH) approach for the detection of t(9;11)(p22-23;q23) in acute myeloid leukemia. 218
Alterations of loci encoding PU.1, BOB1, and OCT2 transcription regulators do not correlate with their suppressed expression in Hodgkin lymphoma. 217
Identifying High-Risk Chronic Lymphocytic Leukemia: A Reappraisal of the Impact of Prognostic and Predictive Factors 217
APPLICATION of EUTOS SCORE IN CHRONIC Myeloid LEUKEMIA AFFECTING VERY Elderly (>75 years) PATIENTS 215
THE EUTOS LONG-TERM SURVIVAL SCORE IS PREDICTIVE FOR RESPONSE AND OUTCOME IN CML PATIENTS TREATED FRONTLINE WITH NILOTINIB-BASED REGIMENS 215
Chromosome 14q32 translocations involving the immunoglobulin heavy chain locus in chronic lymphocytic leukaemia identify a disease subset with poor prognosis 214
Functional integrity of the p53-mediated apoptotic pathway induced by the nongenotoxic agent nutlin-3 in B-cell chronic lymphocytic leukemia (B-CLL) 212
Detection of inherited chromosomally integrated HHV-6 (ciHHV-6) in a marker chromosome 211
Molecular cytogenetic characterization of marginal zone B-cell lymphoma: correlation with clinicopathologic findings in 14 cases 208
MicroRNAs involvement in fludarabine refractory chronic lymphocytic leukemia 207
Four novel non-random chromosome rearrangements in B-cell chronic lymphocytic leukaemia: 6p24-25 and 12p12-13 translocations, 4q21 anomalies and monosomy 21 207
“Hemophagocytic Lymphohistiocytosis after EBV reactivation and ibrutinib treatment in relapsed/refractory Chronic Lymphocytic Leukemia” 202
Abnormalities of chromosomes 1p34-36, 4p16, 4q35, 9q11-32 and +7 represent novel recurrent cytogenetic rearrangements in chronic lymphocytic leukemia 201
In chronic lymphocytic leukaemia, SLAMF1 deregulation is associated with genomic complexity and independently predicts a worse outcome 198
LATE APPEARANCE of 14q32/IGH TRANSLOCATION In CHRONIC LYMPHOCYTIC LEUKEMIA. 196
Cytogenetic and molecular cytogenetic characterization of 6 new cases of idiopathic hypereosinophilic syndrome 193
Clonal evolution in chronic lymphocytic leukemia: analysis of clinicobiologic correlations in 105 patients 192
Expression of the immunoglobulin superfamily cell membrane adhesion molecule Cd146 in acute leukemia 192
Multilineage involvement in the 5q- syndrome: A fluorescent in situ hybridization study on bone marrow smears 191
Circulating endothelial cells in patients with chronic lymphocytic leukemia: clinical-prognostic and biological significance 191
Peripheral T-cell lymphoma not otherwise specified (PTCL-NOS) 191
Hepatosplenic T-cell lymphoma (HSTCL). 190
Hemophagocytic Lymphohistiocytosis in a Patient with Relapsed Chronic Lymphocytic Leukemia Treated with Ibrutinib 190
A population-based study of chronic myeloid leukemia patients treated with imatinib in first line 190
CLINICAL AND BIOLOGICAL CHARACTERIZATION OF CIRCULATING ENDOTHELIAL CELLS IN CHRONIC LYMPHOCYTIC LEUKEMIA 189
Long-term outcome of chronic myeloid leukemia patients treated frontline with imatinib 189
TYROSINE KINASE INHIBITORS DISCONTINUATION IN CHRONIC MYELOID LEUKEMIA: A RETROSPECTIVE ANALYSIS OF 208 ITALIAN PATIENTS 189
The combination of complex karyotype subtypes and IGHV mutational status identifies new prognostic and predictive groups in chronic lymphocytic leukaemia 184
Differences among young adults, adults and elderly chronic myeloid leukemia patients 184
Efficacy and Safety of Ruxolitinib in Elderly Patients (> 75 years) with Myelofibrosis 182
Neoplastic circulating endothelial cells in hematologic malignancies 179
Imatinib in very elderly patients with chronic myeloid leukemia in chronic phase: A retrospective study 177
Intestinal T-cell lymphoma 176
Clinicobiological features in chronic lymphocytic leukemia with 14q32/IgH translocations. 175
The BCR-ABL1 transcript type influences response and outcome in Philadelphia chromosome-positive chronic myeloid leukemia patients treated frontline with imatinib 175
Proliferation centers in chronic lymphocytic leukemia: correlation with cytogenetic and clinicobiological features in consecutive patients analyzed on tissue microarrays 172
Clinicobiologic importance of cytogenetic lesions in chronic lymphocytic leukemia 172
Essential Thrombocythemia (ET) 170
EFFICACY AND SAFETY PROFILE OF DASATINIB IN A SUBSET OF VERY ELDERLY PATIENS WITH CHRONIC MYELOID LEUKEMIA (CML) RESISTANT/INTOLERANT TO IMATINIB 169
Outcome of 82 chronic myeloid leukemia patients treated with nilotinib or dasatinib after failure of two prior tyrosine kinase inhibitors 169
VERY ELDERLY CP-CML PATIENTS TREATED WITH IMATINIB FRONTLINE: HAVE CONCOMITANT THERAPIES AN IMPACT ON OUTCOME AND TOXICITY? 169
Dasatinib is safe and effective in unselected chronic myeloid leukaemia elderly patients resistant/intolerant to imatinib 167
Incidence, risk factors and management of pleural effusions during dasatinib treatment in unselected elderly patients with chronic myelogenous leukaemia 161
Long-term outcome of a phase 2 trial with nilotinib 400 mg twice daily in first-line treatment of chronic myeloid leukemia 159
Outcome of Patients with CML Treated with Dasatinib or Nilotinib after Failure of Second Prior TKIs. 158
Molecular cytogenetic lesions in chronic lymphocytic leukemia 158
A Tangle of Genomic Aberrations Drives Multiple Myeloma and Correlates with Clinical Aggressiveness of the Disease: A Comprehensive Review from a Biological Perspective to Clinical Trial Results 156
First-Line Treatment of Older Patients with CLL: A New Approach in the Chemo-Free Era 155
Increased serum levels of matrix metalloproteinase-9 predict clinical outcome of patients with early B-cell chronic lymphocytic leukaemia 155
TREATMENT, RESPONSE, AND OUTCOME IN UNSELECTED ELDERLY PATIENTS WITH NEWLY DIAGNOSED, CHRONIC PHASE (CP), PHILADELPHIA CHROMOSOME-POSITIVE (PH plus ) CHRONIC MYELOID LEUKEMIA 155
PAX5/IGH rearrangement is a recurrent finding in a subset of aggressive B-NHL with complex chromosomal rearrangements 154
Trisomy 8 in PDGFRB-negative cells in a patient with imatinib-sensitive chronic myelomonocytic leukemia and t(5;16)(q33;p13) PDGFRB-NDE1 fusion 154
IN CHRONIC LYMPHOCYTIC LEUKEMIA THE AMOUNT OF PROLIFERATION CENTERS IN TISSUE-BIOPSIES CORRELATES WITH UNFAVORABLE CYTOGENETIC ABNORMALITIES 154
Modern treatment in chronic lymphocytic leukemia: impact on survival and efficacy in high-risk subgroups. 149
Predictors for Response to Ruxolitinib in Real-Life: An Observational Independent Study on 408 Patients with Myelofibrosis 148
Capitolo 1. Fisiopatologia del sangue e degli organi ematopoietici. 147
Ibrutinib and Rituximab in Waldenström's Macroglobulinemia (letter) 147
Dasatinib, even at low doses, is an effective second-line therapy for chronic myeloid leukemia patients resistant or intolerant to imatinib. Results from a real life-based Italian multicenter retrospective study on 114 patients. 146
The complex karyotype landscape in chronic lymphocytic leukemia allows to refine the risk of Richter syndrome transformation 145
Peripheral blasts are associated with responses to ruxolitinib and outcomes in patients with chronic-phase myelofibrosis 144
Imatinib in Very Elderly (> 75 years) CML Patients: Are Low-Doses (<400 mg daily) Enough? 144
The Dose and the duration of frontline therapy with Imatinib does not affect response to Dasatinib in Imatinib-Resistant or -intolerant patients with chronic myeloid leukemia (CML). Results from a real Life-Based Italian Multicenter retrospective study on 124 Patients. 143
Imatinib In Very Elderly CML Patients: What Can We Achieve? 142
Totale 20.350
Salva come PNG Salva come JPEG
Categoria #
all - tutte 128.871
article - articoli 0
book - libri 0
conference - conferenze 0
curatela - curatele 0
other - altro 0
patent - brevetti 0
selected - selezionate 0
volume - volumi 6.701
Totale 135.572
Salva come PNG Salva come JPEG


Totale Lug Ago Sett Ott Nov Dic Gen Feb Mar Apr Mag Giu
2020/2021190 0 0 0 0 0 0 0 0 0 0 0 190
2021/20221.647 129 188 54 59 84 112 93 97 44 137 163 487
2022/20231.579 180 88 64 182 259 209 74 167 210 7 89 50
2023/2024780 79 91 37 18 38 143 42 54 24 16 26 212
2024/20253.717 94 102 273 101 488 363 68 149 648 406 510 515
2025/202612.061 993 566 907 1.465 1.626 782 1.296 699 1.162 1.286 826 453
Totale 28.887